Pharmaceutical

BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

Jan 6, 2025 - 06:00
BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.
Read the original article

Tags:

Previous Article

China’s NMPA approves GSK’s Nucala for CRSwNP treatment

Next Article

Coronavirus Disease 2019 (COVID-19) vaccine by China National Biotec Group for C...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC approves Daiichi Sankyo’s Vanflyta for acute myeloid leukaemia

EC approves Daiichi Sankyo’s Vanflyta for acute myeloid...

Nov 12, 2023

Free Covid tests will be offered again to all U.S. households

Free Covid tests will be offered again to all U.S. hous...

Sep 20, 2023

EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma

EMA’s CHMP recommends Sanofi’s Sarclisa approval for mu...

Nov 15, 2024